Barry Peters

Type 2 diabetes prevalence and its risk factors in HIV: A cross-sectional study

Alastair Duncan, Louise M. Goff, Barry Peters · PLoS ONE · 2018 · 124 citations · Full text

Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial

Ulrik Bak Dragsted, Jan Gerstoft, Court Pedersen et al. · The Journal of Infectious Diseases · 2003 · 118 citations · Full text

Assigned Treatment, Adverse Events, Indinavir/ritonavir Versus Saquinavir/ritonavir +13

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity

Barry Peters, Walter Jaoko, Eftyhia Vardas et al. · Vaccine · 2006 · 109 citations

Vaccination, Vaccine Development, Immunology +6

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

Richard B. Pollard, Jürgen K. Rockstroh, Giuseppe Pantaleo et al. · The Lancet Infectious Diseases · 2014 · 107 citations · Full text

Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS

Barry Peters, J. Winer, D. N. Landon et al. · QJM · 1993 · 100 citations